Natural health products in the prevention and treatment of osteoporosis: Systematic review of randomized controlled trials

Annals of Pharmacotherapy

Volumn 40, Issue 5, 2006, Pages 836-849

  Whelan, Anne Marie ^a   Jurgens, Tannis M ^a   Bowles, Susan K ^b,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c Centre for Health Care of the Elderly   (Canada)

Author keywords

DHEA; Dietary supplements; Natural health products; Osteoporosis; Phytoestrogens; Vitamin K 2

Indexed keywords

BIOCHANIN A; BLACK TEA EXTRACT; CALCIUM; CHONDROITIN; CONJUGATED ESTROGEN; DAIDZEIN; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ETIDRONIC ACID; FARNOQUINONE; FISH OIL; FOLIC ACID; FORMONONETIN; GENISTEIN; GLYCITEIN; ISOFLAVONE; ISOFLAVONE DERIVATIVE; MEDROXYPROGESTERONE ACETATE; MELATONIN; MENATETRENONE; NATURAL PRODUCT; PHYTOESTROGEN; PRASTERONE; PRIMROSE OIL; PROGESTERONE; SOYBEAN PROTEIN; UNINDEXED DRUG; VITAMIN D; VITAMIN K GROUP; WARFARIN;

ABDOMINAL DISTENSION; ACNE; ALFALFA; ALTHAEA; ANGELICA SINENSIS; ARTHRALGIA; AVOCADO; BLACK PEPPER; BONE DENSITY; BONE MINERAL; BONE PAIN; BREAST CANCER; BREAST DISEASE; CABBAGE; CIMICIFUGA RACEMOSA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DANDELION; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; EQUISETUM; FATIGUE; FLATULENCE; FLUID RETENTION; GINSENG; GLYCYRRHIZA; HEADACHE; HERBAL MEDICINE; HIRSUTISM; HUMAN; HYPERTENSION; MALAISE; MENOPAUSAL SYNDROME; MENSTRUATION DISORDER; NAUSEA; OSTEOPOROSIS; PAPAYA; PHYTOTHERAPY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RUMEX; SKIN IRRITATION; SLEEP DISORDER; STOMACH IRRITATION; SYSTEMATIC REVIEW; TEA; THORAX PAIN; TREATMENT OUTCOME; TUMOR; VOMITING;

BIOLOGICAL PRODUCTS; BONE DENSITY; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PHYTOESTROGENS; PLANT PREPARATIONS; RANDOMIZED CONTROLLED TRIALS;

EID: 33646762771     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G226     Document Type: Review

References (55)

1. Bone health and osteoporosis: a report of the surgeon general. Rockville MD: US Department of Health and Human Services, Office of the Surgeon General, 2004. www.surgeongeneral.gov/library/bonehealth/content. html (accessed 2005 June 15).
2. Brown JP, Josse RG. Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;156(suppl):S1-34.
3. Yuen CK, Kendler D, Khan AA, Brown J, Fortier M. Osteoporosis: Canadian consensus on menopause and osteoporosis. JOGC 2002;24:35-45.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
5. Hulley S, Furberg C, Barrett-Cormor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
6. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in post-menopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651-62.
7. Austin PC, Mamdani MM, Tu K, Jaakkimainen L. Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study (letter). JAMA 2003;289:3241-2.
8. Lawton B, Rose S, McLeod D, Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. BMJ 2003;327:845-6.
9. Ettinger B, Grady D, Tosteson ANA, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue post-menopausal hormone therapy. Obstet Gynecol 2003;102:1225-32.
10. Express Scripts. Many women stop combination hormone replacement-HRT- therapy but 57 percent continue HRT following health risk reports. Media release. 2003, Jan 9. www.express-scripts.com (accessed 2003 Dec 11).
11. Haskell SG. After the Women's Health Initiative: postmenopausal women's experiences with discontinuing estrogen replacement therapy. J Womens Health 2004;13:438-42.
12. Anderson DL, Shane-McWhorter L, Crouch BI, Andersen SJ. Prevalence and patterns of alternative medication use in a university hospital outpatient clinic serving rheumatology and geriatric patients. Pharmacotherapy 2000;20:958-66.
13. Yoon SJ, Horne CH. Herbal products and conventional medicines used by community-residing older women. J Adv Nurs 2001;33:51-9.
14. Mahady GB, Parrot J, Lee C, Yun GS, Dan A. Botanical dietary supplement use in peri- and postmenopausal women. Menopause 2003;10:65-72.
15. Jellin JM, ed. Natural medicines comprehensive database. Stockton, CA. www.naturaldatabase.com (accessed 2004 Jun 14)
16. Bratman S, Girman AM, eds. Mosby's handbook of herbs and supplements and their therapeutic uses. St. Louis: Mosby, 2002.
17. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clin Trials 1996;17:1-12.
18. Shea B, Wells G, Cranney A, et al. Calcium supplementation on bone loss in postmenopausal women (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, 2003.
19. Morgan SL. Calcium and vitamin D in osteoporosis. Rheum Dis Clin North Am 2001;27:101-30.
20. Meunier PJ. Calcium, vitamin D and vitamin K in the prevention of fractures due to osteoporosis. Osteoporos Int 1999;9(suppl 2):S48-52.
21. Gillespie WJ, Avenell A, Henry DA, O'Connell DL, Robertson J. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, 2003.
22. Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:560-9.
23. Haguenauer D, Welch V, Shea B, Wells G. Fluoride for treating post-menopausal osteoporosis (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, UK: John Wiley & Sons, 2003.
24. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68.
25. Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A 2000;97:4279-84.
26. Morales AJ, Haubrich RH, Hwang JY, Asakura H, Yen SSC. The effect of six months of treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol 1998;49:421-32.
27. Alekel DL, St Germain A, Peterson CT, Hanson KB, Steward JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 2000;72:844-52.
28. Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2004;79:326-33.
29. Chen Y, Ho SC, Lam SSH, Ho SSS, Woo JLF. Soy isoflavones have a favourable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind randomized, controlled trial. J Clin Endocrinol Metab 2003;88:4740-7.
30. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001;8:259-65.
31. Dalais FS, Rice GE, Wahlqvist ML, et al. Effects of dietary phytoestrogens in postmenopausal women. Climacteric 1998;1:128-9.
32. Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. Menopause 2004;11:290-8.
33. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women. JAMA 2004;292:65-74.
34. Lydeking-Olsen E, Beck-Jensen J, Setchell KDR, Holm-Jensen T. Soymilk or progesterone for prevention of bone loss-a 2 year randomized, placebo-controlled trial. Eur J Nutr 2004;43:246-57.
35. Morabito N, Crisafulli A, Vegara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early post-menopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 2002;17:1904-12.
36. Potter SM, Baum J, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68(6 suppl):1375S-9S.
37. Uesugi T, Toda T, Okuhira T, Chen JT. Evidence of estrogenic effect by the three-month intervention of isoflavone on vaginal maturation and bone metabolism in early postmenopausal women. Endocr J 2003;50:613-9.
38. 2 on bone mineral density in postmenopausal women: a comparative study with vitamin D3 and estrogen-progestin therapy. Maturitas 1999;31:161-4.
39. 2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. J Orthop Sci 2000;5:546-51.
40. Iwamoto J, Takeda T, Ichimura S. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J Orthop Sci 2001;6:487-92.
41. 2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000;15:515-21.
42. 3 on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas 2002;41:211-21.
43. Strause L, Saltman P, Smith KT, Bracker M, Andon MB. Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals. J Nutr 1994;124:1060-4.
44. Bassey EJ, Littlewood JJ, Rothwell MC, Pye DW. Lack of effect of supplementation with essential fatty acids on mineral density in healthy pre- and postmenopausal women: two randomized controlled trials of Efacal v. calcium alone. Br J Nutr 2000;83:629-35.
45. Kruger MC, Coetzer H, de Winter R, Gericke G, van Papendorp DH. Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis. Aging 1998;10:385-94.
46. Pepping J. DHEA: dehydroepiandrosterone. Am J Health Syst Pharm 2000;57:2048-50, 2053-4, 2056.
47. Mackowiak ED, Tu P. Dehydroepiandrosterone: does it have a role in osteoporosis? US Pharmacist 2000;25:62-70.
48. Glazier MG, Bowman MA. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 2001;161:1161-72.
49. Anderson JJ, Anthony MS, Cline JM, Washburn SA, Garner SC. Health potential of soy isoflavones for menopausal women. Pub Health Nutr 1999;2:489-504.
50. Murkies AL, Wilcox G, Davis SR. Clinical review 92: phytoestrogens. J Clin Endocrinol Metab 1998;83:297-303.
51. Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am 2000;14:339-53.
52. Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. J Nutr 1996;126(4 suppl):1181S-6S.
53. Weber P. Management of osteoporosis: is there a role for vitamin K? Int J Vitam Nutr Res 1997;67:350-6.
54. Rosen CJ. Pre-emptive bone strikes in prevention of osteoporosis. Lancet 1998;351:927-8.
55. Black D. Epidemiology of osteoporosis-update from the ASBMR. www.medscape.com/viewarticle/443218 (accessed 2005 Aug 23).